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In addition to their immune cell origin and immunological effects, cytokines are produced by neuronal and glial cells and can 
influence nerve growth and plasticity. Likewise, in addition to their target tissue origin and neurotrophic effects, the 
neurotrophins nerve growth factor and brain-derived neurotrophic factor are secreted by immune cells and can promote 
immune cell growth and activity. Cytokines jznd neurotrophic factors are thus essential mediators in the complex network of 
neuroimmunoendocrine interactions. Psychiatric patients, as well as psychotropic drugs, can display abnormal expression of 
these molecules and their receptors. Such studies point to the potential contribution of both cytokines and neurotrophins to the 
neuropathology of certain psychiatric diseases. This article highlights the role played by the cytokines interleukin-1,-2,-3,-6 and 
by the neurotrophins nerve growth factor and brain-derived neurotrophic factor in the development of schizophrenia and 
depression. Biomed Rev 1999; 10: 69-73. 
 
INTRODUCTION 
Cytokines are multifunctional molecules secreted (synthesized, 
usually stored, and released) by a wide variety of cells in the 
body, using para-, auto-, and endocrine pathways (1-3). The 
cytokine research began in 1944, when Menkin reported the 
isolation of a fever-inducing factor, pyroxin, from inflammatory 
exudate (4). Subsequent studies demonstrated that lymphocyte-
derived humoral factors exert proliferative effect on 
lymphocytes (5,6). Such substances secreted by immune and 
inflammatory cells were named lymphokines, monokines, 
interleukins (ILs), and interferons, until the term "cytokines" 
embodied these all molecules, targeted to multiple cells within 
specific networks (1-3). This heterogeneous group of 
glycoproteins has a number of common characteristics, both in 
structure and function. Likewise, individual cytokines exert 
multiple overlapping cell regulatory effects, interacting in a 
network by (/) inducing each other, (ii) modulating cytokine cell 
surface receptors, and (Hi) 
exerting synergistic, additive or antagonistic effects on a given 
cell function (1). In a broader sense, "cytokines" is a term which 
overlaps both "growth factors" and "hormones". Cytokines 
and neurotrophic factors, including ILs, tumor necrosis factor-
alpha (TNF-cc), nerve growth factor (NGF), and brain-derived 
neurotrophic factor (BDNF), play an important role in many 
physiological responses, are involved in the pathobiology of 
various diseases, and have certain therapeutic potentials (1-
3,7-10). NGF and BDNF are members of the neurotrophin family of 
proteins which also includes neurotrophin-3 (NT-3), NT-4/ 5, 
and NT-6 (7,9). Neurotrophins play crucial roles in 
differentiation, survival, and activity of specific populations of 
central and peripheral neurons. In addition, various nonneuronal 
cells are responsive to neurotrophins (7,9), as well as cytokines 
elicit various effects from neuronal and glial cells (11,12). 
Since Aloe and Levi-Montalcini's first demonstration (in 
1977) of NGF-induced increase in the number of mast cells in 
various tissues, and Besedovsky et al's first demonstration (in 
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1986) that IL-1 treatment increases the plasma levels of neuro-
hormones, there is accumulating evidence of interactions 
among the cells of nervous, immune and endocrine system 
(reviewed in 13-17). Cytokines and neurotrophins play a central 
role in the mediation of these interactions. Furthermore, 
cytokines are not only important regulatory factors in immune 
and inflammatory processes, but also exert neurotrophic activity 
of their own (18) or indirectly, through upregulation of 
neurotrophin expression (11,12,19). Likewise, it is very likely 
that the neuroendocrine system may produce a variety of 
cytokines, just as immune system produces a plethora of 
neuroendocrine hormones, neurotrophic factors, and neuropep-
tide neurotransmitters (13-16). 
In this article, I will focus on the involvement of various 
cytokines, particularly, IL-1, IL-2, IL-3, and IL-6 in the patho-
biology of schizophrenia and depression. Also, implications 
of NGF and BDNF in these diseases, as well as of antipsy-
chotic and antidepressant drugs in the biology of cytokines 
and neurotrophins, will be outlined. 
CYTOKINES AND NEUROTROPHIMS IN SCHIZOPHRENIA 
Schizophrenia is a severe psychiatric disease affecting 
approximately 1% of the population worldwide. Although there is 
evidence of an important genetic contribution to schizophrenia, 
its etiology is largely unknown. Perhaps equally important are 
findings that such a genetic contribution is only part of this 
multiplex disease. Accumulating evidence suggests that 
impaired brain neurogenesis and neurotopogenesis might 
prominently be involved in the neuropathology of 
schizophrenia, leading to the brain developmental hypothesis 
of schizophrenia (reviewed in 20,21). Based on this hypothesis, 
also on the neuroimmunoendocrine pathyaws implicated in 
this disease (19), both cytokines and neurotrophins are 
increasingly pursued in the study of pathogenesis of 
schizophrenia. 
Cytokines and schizophrenia 
Given the effects of cytokines on neuronal and immune cell 
growth and activity and on synaptic neurotransmission and 
plasticity, it would not be surprising if some, cytokine 
production-inducing environmental events, such as birth trauma, 
maternal viral infections, and nutritional disorders, are 
implicated in schizophrenia. Likewise, it is known that during 
clinical trials of cytokines for therapy of various diseases, 
patients exhibited schizophrenia-like symptoms. 
Hypothesis on relationship between ILs and schizophrenia 
was reported in 1995 by Holden and Pakula (22). These authors 
also suggested estrogen as a possible therapeutic option, since 
estrogen could inhibit IL-6 production. Certain epidemiologi-
cal evidences further support such an immunological 
hypothesis, showing that women are more likely to develop 
schizophrenia during menopause and less likely during 






In 1995, we reported that exposure of rats to restrictive stress 
upregulated IL-1 expression in the hypothalamus (23). Since 
the elevation was observed within a few minutes after loading 
the stress, we suggested that IL-1 was produced not by 
translation of mRNAIL"' into protein, but by IL-1 converting 
enzyme, from the neuronal pool of proIL-1. Recent work 
supported these findings (24). In 1991, we reported that 
circulating plasma levels of IL-6 are elevated in schizophrenic 
patients (25). Further, accumulating findings provide supportive 
evidence that IL-1 (3 and IL-6 plasma levels (26,27) as well as 
cere-brospinal fluid IL-1 and IL-2 levels (28) are significantly high 
in schizophrenic patients. Other studies also demonstrate altered 
circulating levels of IL-1 and EL-3 (29), IL-1 andTNF-a(30),IL-2 
(31), and soluble IL-2 receptor, IL-6, and IL-1 receptor antagonist 
(IL-IRa) (32) in patients with schizophrenia. Figure 1 illustrates 
the elevated IL-6 plasma levels in medicated chronic 
schizophrenia patients. 
Altogether, a conclusion is approached that various pro-
inflammatory cytokines may associate with the development of 
schizophrenia (33,34). It is noteworthy that the circulating 
cytokine levels are significantly higher in acute than in remission 
phase of the disease. And the administration of various 
psychotropic drugs results in greater expression of mRNAIL IRa 
than that of mRNAIL'lp in the brain (35). Furthermore, genetic 
analyses of the polymorphism of IL-1 gene complex suggest that 
cytokine abnormalities in schizophrenia are, at least partly, 
genetically determined (36). 
Neurotrophins and schizophrenia 
As indicated above (20,21), neuropalhological findings have 
suggested that schizophrenia development could be related to 
defective embryology in specific brain areas, thus predisposing 
and/or leading to abnormal neuronal circuitry and function in 
the mature brain. NGF and BDNF are highly expressed in the 
brain and a variety of brain neurons are able to secrete and 
respond to the action of these neurotrophins during embryonic 
and early and late postnatal life (37), and also to various 
environmental stimuli (38). Because of their crucial roles in 
neurogenesis and neurotopogenesis, it has been hypothesized 
that significant alterations in the secretion of neurortrophins 
during critical developmental time could alter the function of 
specific brain neurons in pre- and postnatal life, thus 
neurotrophins may be involved in the pathogenesis of 
schizophrenia (39-44). As indicated above for a link between 
antipsy-chotic medication and cytokines (35), there is also such a 
link between the neuroleptic haloperidol and the levels of 
NGF in both hypothalamus and blood plasma (45,46). 
CYTOKIHES AMD HEUROTROPHIMS IM DEPRESSION 
Depression is a disease that affect hundreds of millions of 
people worldwide. Generally, studies addressing both the 
pathogenesis and the therapy of depression are focused on 
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the monoamine hypothesis. That is, the role played by the 
brain neurotransmitters 5-hydroxytryptamine (5-HT; serotonin) 
and noradrenaline (NA). However, recent studies also suggest 
an important role for both cytokines and neurotrophins in the 
neuropathology of depression. 
Cytokines and depression 
The abnormalities seen in depressive patients might be a 
reflection of some balance failure in certain cytokine networks in 
the brain (47). Plasma levels of IL-1J3, IL-6, soluble IL-2, and 
transferrin receptors are altered in patients with major 
depression (48). This is especially associated with patients 
with tri-cyclic antidepressant-resistant depression (refractory 
depression). Further, Kanba et al (49) reported a negative 
correlation between severity of depression and lymphoblast 
transformation, implying some abnormality in the signal 
transduction events in "depressed" lymphocytes. 
Neurotrophins and depression 
While the classical study of depression is mainly focused on 
the brain serotonergic and noradrenergic neurons, emerging 
evidence demonstrates a potential link between neurotrophins 
and depression, as a subtle form of neurodegenerative disease 
(reviewed in 50). For instance, BDNF and NT-3 are reported to 
promote the growth and function of 5-HT- and NA-containing 
 
neurons in the adult brain. Likewise, stress, which often 
positively correlates with depression development, is shown 
to decrease mRANBDNF(50). Note that NGF (51) and BDNF (52) 
are also implicated in epilepsy. In is also noteworthy that 5-HT-
and also NA-targeted antidepressants can work to promote 
the serotonergic and adrenergic neurons by increasing the 
endogenous BDNF and/or NT-3 brain levels, thus suggesting 
that neurotrophin-releasing agents may be a canditate of new 
generation antidepressants (50,53). Accordingly, since human 
platelets contain BDNF (54) and are linked to depression (50) 
and schizophrenia (42), and since lymphocytes produce NGF 
(13), these all cells could be peripheral markers for (f) 
alterations in neurotrophin levels in these psychiatric 
diseases, and (if) neurotrophin responses to antipsychotic and 
antide-pressant drugs. 
CONCLUSION 
The studies discussed above, taken together, strongly suggest 
that dysfunction(s) in the neuroimmunoendocrine pathways 
mediated by certain cytokines and neurotrophins could 
interactively be involved in the neuropathology of 
schizophrenia and depression. Potential involvement of 
cytokines derived from adipose tissue and from thymus and 
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